Bio-Techne Corp (NASDAQ: TECH)’s stock price has increased by 2.45 compared to its previous closing price of 49.88. However, the company has seen a 4.76% increase in its stock price over the last five trading sessions. prnewswire.com reported 2025-06-10 that ST. PAUL, Minn., June 10, 2025 /PRNewswire/ — ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.
Is It Worth Investing in Bio-Techne Corp (NASDAQ: TECH) Right Now?
Bio-Techne Corp (NASDAQ: TECH) has a price-to-earnings ratio that is above its average at 62.29x. The stock has a 36-month beta value of 1.38. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 3 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for TECH is 154.99M, and at present, short sellers hold a 4.65% of that float. On June 10, 2025, the average trading volume of TECH was 2.34M shares.
TECH’s Market Performance
The stock of Bio-Techne Corp (TECH) has seen a 4.76% increase in the past week, with a 2.32% rise in the past month, and a -12.60% fall in the past quarter. The volatility ratio for the week is 2.57%, and the volatility levels for the past 30 days are at 3.39% for TECH. The simple moving average for the past 20 days is 4.82% for TECH’s stock, with a -22.75% simple moving average for the past 200 days.
Analysts’ Opinion of TECH
Many brokerage firms have already submitted their reports for TECH stocks, with Wells Fargo repeating the rating for TECH by listing it as a “Overweight.” The predicted price for TECH in the upcoming period, according to Wells Fargo is $59 based on the research report published on May 30, 2025 of the current year 2025.
Evercore ISI gave a rating of “Outperform” to TECH, setting the target price at $75 in the report published on March 18th of the current year.
TECH Trading at 1.73% from the 50-Day Moving Average
After a stumble in the market that brought TECH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.89% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at TECH starting from JOSHUA MOLHO, who proposed sale 1,280 shares at the price of $49.77 back on Jun 09 ’25. After this action, JOSHUA MOLHO now owns shares of Bio-Techne Corp, valued at $63,705 using the latest closing price.
Herr Amy E., the Director of Bio-Techne Corp, sale 1,860 shares at $65.96 during a trade that took place back on Feb 14 ’25, which means that Herr Amy E. is holding 1,976 shares at $122,691 based on the most recent closing price.
Stock Fundamentals for TECH
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.66 for the gross margin
The net margin for Bio-Techne Corp stands at 0.11. The total capital return value is set at 0.08. Equity return is now at value 6.53, with 4.91 for asset returns.
Based on Bio-Techne Corp (TECH), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.63. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 30.02.
Currently, EBITDA for the company is 310.37 million with net debt to EBITDA at 0.99. When we switch over and look at the enterprise to sales, we see a ratio of 6.92. The receivables turnover for the company is 5.1for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
To sum up, Bio-Techne Corp (TECH) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
